| P50 | author | Ellen Mosley-Thompson | Q55381614 |
| P2093 | author name string | Komal Sodhi | |
| | Krithika Srikanthan | |
| | Nitin Puri | |
| | Rebecca Klug | |
| | Joseph Shapiro | |
| | Maria Tirona | |
| | Haresh Visweshwar | |
| P2860 | cites work | MicroRNAs in cardiomyocyte development | Q24596454 |
| | A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure | Q24673535 |
| | MicroRNAs in Valvular Heart Diseases: Potential Role as Markers and Actors of Valvular and Cardiac Remodeling | Q26740102 |
| | Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity | Q27027354 |
| | Perturbation of microRNAs in rat heart during chronic doxorubicin treatment | Q27335046 |
| | MicroRNAs in cardiovascular disease: an introduction for clinicians | Q28084229 |
| | Cardiac dysfunction in the trastuzumab clinical trials experience | Q28204298 |
| | The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia | Q28271441 |
| | Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin | Q28376449 |
| | miR-150 regulates high glucose-induced cardiomyocyte hypertrophy by targeting the transcriptional co-activator p300 | Q28583589 |
| | The MicroRNA Spectrum in 12 Body Fluids | Q29618068 |
| | Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies | Q30426853 |
| | Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy | Q33180853 |
| | Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy | Q33183838 |
| | Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy | Q33202989 |
| | Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition | Q33263478 |
| | Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation | Q33647686 |
| | Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children | Q46328753 |
| | C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction | Q47191457 |
| | The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling | Q47245105 |
| | MicroRNA-150: a novel marker of left ventricular remodeling after acute myocardial infarction | Q48101030 |
| | Circulating mir-208a fails as a biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients | Q48178650 |
| | Development of doxorubicin-induced chronic cardiotoxicity in the B6C3F1 mouse model. | Q50500648 |
| | Chemotherapy-induced Cardiotoxicity. | Q51224671 |
| | Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells. | Q53600752 |
| | Plasma miR-208 as a useful biomarker for drug-induced cardiotoxicity in rats. | Q54195804 |
| | Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. | Q54408211 |
| | Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies | Q57636819 |
| | Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits | Q58841724 |
| | Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane | Q64387817 |
| | Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group | Q68114949 |
| | Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human Hearts | Q72933722 |
| | Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes | Q73894487 |
| | Cardiac troponin I in patients with hematologic malignancies | Q74051227 |
| | Cardiac troponin I as diagnostic and prognostic marker in severe heart failure | Q74128600 |
| | Guidelines for clinical use of cardiac radionuclide imaging: A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (Committee on Radionuclide Imagin | Q74173636 |
| | Troponin T in the first 24 hours after the administration of chemotherapy and the detection of myocardial damage in children | Q77828173 |
| | Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy | Q78863341 |
| | Troponin I and cardiovascular risk stratification in patients with testicular cancer | Q79930506 |
| | cTnT can be a useful marker for early detection of anthracycline cardiotoxicity | Q81537650 |
| | Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity | Q81698731 |
| | NT-proBNP: a cardiac biomarker to assess prognosis in non-Hodgkin lymphoma | Q83442793 |
| | Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines | Q84424023 |
| | MicroRNA-150 protects the heart from injury by inhibiting monocyte accumulation in a mouse model of acute myocardial infarction | Q86169076 |
| | MicroRNAs expression profiles in cardiovascular diseases | Q33821302 |
| | Identification of the molecular basis of doxorubicin-induced cardiotoxicity | Q34308627 |
| | Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. | Q34429779 |
| | Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy | Q34429785 |
| | Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers | Q34645919 |
| | Pervasive roles of microRNAs in cardiovascular biology | Q34775686 |
| | Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab | Q34855776 |
| | NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. | Q35580797 |
| | MicroRNA-150 protects the mouse heart from ischaemic injury by regulating cell death | Q35661827 |
| | Role of microRNA-150 in solid tumors | Q35803040 |
| | Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes | Q35925266 |
| | MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets | Q35951484 |
| | Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab | Q36339976 |
| | The relevance of information generated by in vitro experimental models to clinical doxorubicin cardiotoxicity | Q36590959 |
| | Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab | Q36988278 |
| | Early detection and prediction of cardiotoxicity in chemotherapy-treated patients | Q36988282 |
| | Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. | Q37293584 |
| | The emerging role of microRNAs in cardiac remodeling and heart failure | Q37319218 |
| | Role of microRNAs in cardiac remodeling and heart failure | Q37856783 |
| | Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity | Q38148968 |
| | Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury | Q38166071 |
| | Mir-34: a new weapon against cancer? | Q38253374 |
| | microRNA-based diagnostics and therapy in cardiovascular disease-Summing up the facts | Q38379481 |
| | Cardiotoxicity due to Chemotherapy: the Role of Biomarkers | Q38508938 |
| | Monitoring for anthracycline cardiotoxicity. | Q38572343 |
| | MicroRNAs play an essential role in the development of cardiac hypertrophy | Q39340872 |
| | Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure | Q40203262 |
| | Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients | Q41245359 |
| | Utility of circulating microRNAs as clinical biomarkers for cardiovascular diseases | Q41359989 |
| | Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography | Q42218798 |
| | A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine | Q42247287 |
| | Circulating MicroRNAs in cardiovascular disease | Q42412503 |
| | Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. | Q42546809 |
| | Early biomarkers of doxorubicin-induced heart injury in a mouse model. | Q42703425 |
| | Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. | Q43607792 |
| | Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy? Multiple gated acquisition | Q43688776 |
| | Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction | Q43897122 |
| | N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? | Q44090143 |
| | Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. | Q44389042 |
| | Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy | Q46245837 |
| P433 | issue | 3 | |
| P921 | main subject | biomarker | Q864574 |
| P577 | publication date | 2017-03-22 | |
| P1433 | published in | Journal of clinical & experimental cardiology | Q27723952 |
| P1476 | title | Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients | |
| P478 | volume | 8 | |